Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.41 -0.4%	$2.04	$1.11 ▼ $5.00	$644.06M	1.81	1.57 million shs	1.50 million shs
CBMG Cellular Biomedicine Group		$19.68	$11.48 ▼ $19.75	$384.69M	1.35	129,776 shs	8,375 shs
DTIL Precision BioSciences	$4.61 -0.6%	$4.73	$3.61 ▼ $11.09	$51.45M	1.43	231,120 shs	108,116 shs
HARP Harpoon Therapeutics	$23.01	$22.89	$3.11 ▼ $23.21	$389.61M	2.11	1.52 million shs	N/A
NK NantKwest	$2.83 +2.9%	$28.01	$2.52 ▼ $45.42	$309.45M	2.61	1.57 million shs	7.25 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-0.82%	-2.42%	+19.21%	+69.23%	-45.37%
CBMG Cellular Biomedicine Group	0.00%	0.00%	0.00%	0.00%	0.00%
DTIL Precision BioSciences	+2.65%	-3.93%	-5.31%	-7.57%	-55.34%
HARP Harpoon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NK NantKwest	+0.36%	-1.43%	-12.14%	+11.34%	-55.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.6855 of 5 stars	3.5	1.0	0.0	0.0	2.6	3.3	0.6
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	4.2796 of 5 stars	3.5	1.0	0.0	4.6	3.1	1.7	1.3
HARP Harpoon Therapeutics	0.7603 of 5 stars	0.0	0.0	0.0	4.7	0.6	2.5	0.0
NK NantKwest	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	286.72% Upside
CBMG Cellular Biomedicine Group	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	919.52% Upside
HARP Harpoon Therapeutics	0.00	N/A	N/A	N/A
NK NantKwest	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HARP, CBMG, AUTL, NK, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	63.38	N/A	N/A	$1.61 per share	1.50
CBMG Cellular Biomedicine Group	$340K	0.00	N/A	N/A	$2.89 per share	0.00
DTIL Precision BioSciences	$68.70M	0.74	N/A	N/A	$6.87 per share	0.67
HARP Harpoon Therapeutics	$37.34M	10.43	N/A	N/A	$1.63 per share	14.12
NK NantKwest	$40K	7,736.16	N/A	N/A	$1.23 per share	2.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	0.00	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
CBMG Cellular Biomedicine Group	-$49.98M	N/A	N/A	N/A	N/A	N/A	-144.80%	-61.68%	N/A
DTIL Precision BioSciences	$7.17M	-$2.01	0.00	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
HARP Harpoon Therapeutics	-$67.73M	-$8.76	N/A	N/A	N/A	-81.68%	-893.55%	-45.98%	N/A
NK NantKwest	-$65.79M	-$0.70	N/A	N/A	N/A	-76,658.58%	-56.06%	-46.93%	N/A

Latest HARP, CBMG, AUTL, NK, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	N/A	N/A	N/A	$6.27 million	N/A
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HARP Harpoon Therapeutics	N/A	N/A	N/A	N/A	N/A
NK NantKwest	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
CBMG Cellular Biomedicine Group	N/A	0.47	0.47
DTIL Precision BioSciences	0.45	6.62	6.62
HARP Harpoon Therapeutics	N/A	1.89	1.89
NK NantKwest	N/A	4.74	4.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CBMG Cellular Biomedicine Group	21.98%
DTIL Precision BioSciences	37.99%
HARP Harpoon Therapeutics	74.01%
NK NantKwest	9.38%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CBMG Cellular Biomedicine Group	8.50%
DTIL Precision BioSciences	4.50%
HARP Harpoon Therapeutics	17.00%
NK NantKwest	71.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CBMG Cellular Biomedicine Group	217	19.48 million	N/A	Optionable
DTIL Precision BioSciences	200	11.09 million	10.59 million	No Data
HARP Harpoon Therapeutics	53	16.93 million	14.05 million	Optionable
NK NantKwest	160	109.35 million	N/A	Not Optionable

HARP, CBMG, AUTL, NK, and DTIL Headlines

Recent News About These Companies

Piper Sandler Upgrades ImmunityBio (IBRX)

May 21, 2025 | msn.com

HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation

March 7, 2025 | msn.com

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

February 4, 2025 | seekingalpha.com

BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation

January 11, 2025 | msn.com

Northern Knights Cricket Team

August 3, 2024 | espncricinfo.comE

Natural Killer Cells Therapeutics Market Projections: Anticipated Trends and Developments

May 27, 2024 | taiwannews.com.twT

From Culture to Clinic: Scale Up NK Cell Expansion

May 1, 2024 | the-scientist.comT

P!nk puts on showstopping performance for first TSV show

March 25, 2024 | townsvillebulletin.com.auT

Space NK Promo Code - Up to £330 off

March 16, 2024 | glamourmagazine.co.ukG

Use of Allogeneic NK Cells for Cancer Immunotherapy

March 2, 2024 | medscape.comM

Space NK Promo Code - Up to £120 off

February 18, 2024 | glamourmagazine.co.ukG

Space Nk Promo Codes

February 4, 2024 | time.comT

NK Industries Ltd.

December 12, 2023 | ndtv.comN

NK Gupta

November 28, 2023 | hindustantimes.comH

P!NK's concert in Phoenix: Acrobatic spectacle, raw emotion and Brandi Carlile's last stop

October 23, 2023 | azcentral.comA

P!NK's 2023 tour setlist: 'Who Knew,' 'So What' and every song she sang in Phoenix

October 18, 2023 | azcentral.comA

Space NK beauty advent calendar 2023 early access waitlist now open

September 15, 2023 | thesun.co.uk

Frankie Bridge shares her new Space NK beauty buys including concealer people 'love'

August 13, 2023 | mirror.co.ukM

Lost metabolic fitness of CAR NK cells is key mechanism of tumor resistance, study discovers

August 3, 2023 | medicalxpress.comM

Formation and function of the lytic NK-cell immunological synapse

July 9, 2023 | nature.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
By Gabriel Osorio-Mazilli | July 3, 2025
View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution

HARP, CBMG, AUTL, NK, and DTIL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.41 -0.01 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.01 (-0.21%)

As of 06:41 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Precision BioSciences NASDAQ:DTIL

$4.61 -0.03 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$4.63 +0.02 (+0.43%)

As of 07:52 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time